HPV vaccination: Too soon for 2 doses?

摘要

CERVICAL CANCER IS THE SECOND MOST COMMON CAN-cer among women globally, according to age-standardized incidence rates. Approximately 530 000 women are diagnosed with cervical cancer and 275 000 die of the disease every year; 88% of deaths occur in developing regions of the world. Human papillo-mavirus (HPV) infection is a well-established cause of cervical cancer as well as other anogenital and oropharyngeal cancers; therefore, prophylactic HPV vaccines have the potential to substantially reduce the incidence of cervical cancer and other HPV-associated diseases. Three-dose schedules of the bivalent vaccine (HPV-16 and -18) and the quadrivalent vaccine (HPV-6, -11,-16, and -18) have been shown to be highly efficacious in preventing persistent infection with HPV-16 and -18, which cause approximately 70% of cervical cancers, as well as precancerous lesions associated with these types. The quadrivalent vaccine has also been shown to prevent anogenital warts associated with HPV-6 and-11.